World CNS Series

Preparations are in full swing for the 7th Neuropsychiatric Drug Development Summit, kicking off in 3 weeks to fuel the next generation of neuropsychiatry approvals. Here’s what’s in store for you: 🌟Share cutting-edge advancements and foster pre-competitive collaboration to innovate precision psychiatry, propel next-generation drug R&D, and fuel more clinical approvals 🗨️ Engage in interactive panel discussions on transforming ‘precision neuropsychiatry’ from idea to realization with Alto Neuroscience, Delix Therapeutics, Compass Pathways, Boehringer Ingelheim 🔍 Discover new next-generation targets, modalities, and technologies from 8+ new presenting companies, including Karuna Therapeutics, Click Therapeutics, Inc. MapLight Therapeutics, Inc., and Sensorium Therapeutics Have a look at the agenda for more detail: https://ter.li/ecg8eq And a big thanks to the partners! Biotrial www.biotrial.com Centre for Human Drug Research www.CHDR.nl bit.bio www.bit.bio Eurofins www.eurofins.ca Ulysses Neuroscience Limited www.ulysses-neuro.ie Sama Therapeutics www.sama.ac SynapCell www.synapcell.com Advanced Brain Monitoring https://lnkd.in/edkmPsM2

🧠 Discover, Validate & Implement Novel Translatable Neuroinflammatory & Neurodegenerative Biomarkers 🧠 Have you seen the agenda for the 𝟮𝗻𝗱 𝗙𝗹𝘂𝗶𝗱 & 𝗜𝗺𝗮𝗴𝗶𝗻𝗴 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 & 𝗘𝗻𝗱𝗽𝗼𝗶𝗻𝘁𝘀 𝗶𝗻 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗦𝘂𝗺𝗺𝗶𝘁? With content spanning discovery, translational, and clinical development to accelerate approval of AD, PD, ALS & MS therapeutics with enhanced neurodegeneration and neuroinflammation biomarker measurements, this summit is not to be missed. Join leaders from Biogen, PTC Therapeutics, Inc., The Michael J. Fox Foundation for Parkinson's Research, Eli Lilly and Company, Alector, Foundation for the National Institutes of Health, AbbVie, Takeda, AC Immune, APRINOIA Therapeutics, Tranquis Therapeutics, Inc., University of Southern California, Eisai US, Neurocrine Biosciences, Passage Bio, Johnson & Johnson, and many more. Secure your pass and take advantage of our discounted rate expiring tomorrow: https://ter.li/tjuxu4 📆 Save the Date: October 22 - 24, 2024 | Boston, MA 🌐 Explore the Agenda: https://ter.li/sxbu9h #CNS #Neuroscience #Alzheimers #Parkinsons #DrugDevelopment #Biomarkers

It was a pleasure to catch up with Iosif (Sifis) Pediaditakis and Mathias Schmidt about their upcoming involvement at the 6th CNS Drug Delivery Summit. Check out the full interviews here https://ter.li/qz9avg to see their insights on: 🧠 How the landscape of CNS drug delivery technologies is evolving 🧠 The development of 2nd generation antibodies with greater brain penetration 🧠 Enhancing the human relevance of in vitro BBB models 🧠 Understanding how BBB dysfunction contributes to neurodegenerative diseases Additionally, view their full presentation details in the 2024 agenda: https://ter.li/rvce1d

🚨 Only 5 days to go! 🚨 The 3rd Digital Biomarkers & Clinical Measures in Neurology Summit is right around the corner, uniting thought leaders to transform the trajectory of clinical development and patient treatment in neurology, in the heart of Boston. Prepare to pull up a chair with an intimate group of experts pioneering in speech, cognition, wearables, actigraphy, software infrastructure, digital therapeutics, commercial scalability and so much more across neurodegeneration, neuromuscular disease, neurodevelopmental disorders and neuropsychiatry. I look forward to welcoming you all to Boston next week! 📆 Save the Date: August 27-29, 2024 | Boston M.A. 🌐 Explore the Agenda: https://ter.li/fc2lzs ✅ Register: https://ter.li/g5ndsg Expert speaker faculty includes: Abhishek Pratap, Ankita Deshpande (She, Her), Bhaskar Dutta, Bola Grace, PhD, MBA, Bruce Morimoto, Carrie Northcott, Elias Abou Zeid, PhD, Erik Hodges, Gayle Wittenberg, Ph.D., Gul Erdemli, Karla Viviani Allebrandt, PD Dr., Katerina Placek, Kathleen Troeger MPH, Mark Gudesblatt, Matteo Bellitti, Qingqin Li, Ram Miller MD MBA FRCPC, Rauha Tulkki-Wilke, Sharon Tamir, Srikanth Gottipati, Viprali Bhatkar, Wolfgang Liedtke and Yuge Xiao Key presenting companies include: Alexion Pharmaceuticals, Inc., Alto Neuroscience, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Cerevel Therapeutics, DEEP Measures, Digital Medicine Society (DiMe), GSK Johnson & Johnson, The Michael J. Fox Foundation for Parkinson's Research, Mitsubishi Tanabe Pharma America, Novartis, Novo Nordisk, Pfizer, Regeneron, Takeda #digitalhealth #digitaltech #digitalbiomarker #digitalendpoint #cns #neuroscience #alzheimers #parkinsons #mdd #depression #schizophrenia #als #neuromuscular #neurodegenerative #neurodegeneration #neurodevelopmental #drugdevelopment #digitaloutcome #digitaltherapeutic

📣Your 2025 Q1 World CNS Series Dates Have Been Released!📣 📅 Mark your calendars: 𝟮𝗻𝗱 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗲𝗴𝗿𝗮𝗱𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗖𝗡𝗦 𝗦𝘂𝗺𝗺𝗶𝘁: https://ter.li/huvb1h | February 18-20 𝟳𝘁𝗵 𝗡𝗲𝘂𝗿𝗼𝗶𝗺𝗺𝘂𝗻𝗼𝗹𝗼𝗴𝘆 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁: https://ter.li/9y0a5o | February 25-27 𝟭𝟯𝘁𝗵 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 & 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻’𝘀 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁: https://ter.li/ah330p | March 18-20

The FDA’s verdict on Lykos Therapeutics’ MDMA-assisted therapy for PTSD, whilst negative news, offers invaluable lessons, highlighting the need for 𝗼𝗽𝗲𝗻 𝗱𝗶𝗮𝗹𝗼𝗴𝘂𝗲 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸𝗲𝗿 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 of psychedelics, and inspiring a renewed commitment to 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝗶𝗻𝗴 𝗙𝗗𝗔 𝗲𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁 with these potentially transformative new treatments. As Josh Hardman posted, “𝘐𝘵’𝘴 𝘸𝘰𝘳𝘵𝘩 𝘦𝘮𝘱𝘩𝘢𝘴𝘪𝘴𝘪𝘯𝘨 𝘵𝘩𝘢𝘵 𝘵𝘩𝘪𝘴 𝘥𝘰𝘦𝘴 𝘯𝘰𝘵 𝘩𝘢𝘷𝘦 𝘵𝘰 𝘣𝘦 𝘵𝘩𝘦 𝘦𝘯𝘥 𝘰𝘧 𝘵𝘩𝘦 𝘳𝘰𝘢𝘥 𝘧𝘰𝘳 𝘔𝘋𝘔𝘈-𝘢𝘴𝘴𝘪𝘴𝘵𝘦𝘥 𝘵𝘩𝘦𝘳𝘢𝘱𝘺’𝘴 𝘍𝘋𝘈 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭 𝘩𝘰𝘱𝘦𝘴, 𝘰𝘳 𝘧𝘰𝘳 𝘓𝘺𝘬𝘰𝘴”, and we should stay tuned for updates in the coming weeks and months. In light of this, the upcoming 𝟳𝘁𝗵 𝗡𝗲𝘂𝗿𝗼𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 is well-timed to serve as a potential 'reset' for the field, offering an opportunity for those at various stages of psychedelic drug development to come together, assess progress, and address these inevitable challenges. With over 60 psychedelic clinical trials currently underway, there's significant progress to monitor from companies like Compass Pathways, MindMed, Cybin Inc, Gilgamesh Pharmaceuticals, Otsuka Pharmaceutical Companies (U.S.), Janssen Inc., Clexio Biosciences, and GH Research plc—all of whom will be present at this year’s summit. Furthermore, preclinical progress from Delix Therapeutics, Psilera, Sensorium Therapeutics and Enveric Biosciences, Inc. will be showcased. We’ll also dive deeper into the psychedelic mode of action and underlying mechanisms with Dalibor Sames, Umed Boltaev and Kurt Rasmussen, and their commercial viability with Robert Discordia, PhD, Dina Burkitbayeva and Elemer Piros. Find all this and more in the full 2024 agenda here: https://ter.li/4r5812 Dan Karlin, Zoë Hughes, PhD, Jackie von Salm, PhD, Guy Goodwin, Gregory Ryslik, Aaron Koenig MD, Jeffrey Brown, Murali Gopalakrishnan, Chris Witowski, PhD, Hadile Ounallah-Saad, Dr. Alex Nivorozhkin, Eliseo Salinas MD MSc, Darrick Balu, Joseph Tucker, Kevin Coveney, CPA, Velichka Valcheva, Gerard Marek, Jeney Zhang

🚨The agenda has officially been released for the 𝟔𝐭𝐡 𝐂𝐍𝐒 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐒𝐮𝐦𝐦𝐢𝐭, arriving in Boston this December 3-5!   Discover the brand-new full event guide here > https://ter.li/riq97k   This is industry’s definitive meeting for cross-functional collaboration across ROAs, modalities, and CNS indications. Unite with 100+ peers from the likes of Biogen, UCB, Novartis, Ionis Pharmaceuticals, Inc., Sanofi, Denali Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson and Roche to advance more translatable systemic and local delivery systems to maximize CNS uptake and safely administer to specific brain regions.   Download the agenda to discover what topics we will explore this year: https://ter.li/riq97k Expert Speakers: Arash Moshkforoush, Bruno MDC Godinho, Christopher Kadamus, Dallas Bednarczyk, Elizabeth Meredith Rhea, Eric D., Haiming Wu, Iosif (Sifis) Pediaditakis, Ismail Hafez, Jingjing Gao, John L. McGuire, Lisa Shafer, Lu Shan, Mathias Schmidt, Max Woolley, Michelle Boyd Ph.D., Nick Todd, Niels Janssen, Pawel Stocki, Peter Horanyi, Rachael Miller, PhD, Sho Sato, Smrithi Padmakumar, Ph.D., Stergios Zacharoulis, Steve Krausert, Vijay Agarwal, William Elmquist, Yuan Yuan, Justin Scheer, Krista Spiller   #CNS #DrugDelivery #Brain #BloodBrainBarrier #BBB

Preparations are in full swing for this year’s 7th Neuropsychiatric Drug Development Summit! Below are some highlights to look out for on this year’s 3-day agenda, the full copy can be accessed here: https://ter.li/l15nir Join 150+ industry leaders for our most comprehensive meeting yet, collaboratively addressing the most pressing scientific, operational, and regulatory challenges for the development of more transformative and precision-based neuropsychiatric candidates. Hurry, early bird savings are on offer this week! Register here https://ter.li/131e9t to claim your discount before it expires this Friday.

The 7th Neuropsychiatric Drug Development Summit is returning this September, convening industry leaders to address the most pressing scientific, operational, and regulatory challenges for the development of transformative neuropsychiatric candidates—including psychedelics and psychoplastogens.   While the agenda isn't exclusively psychedelics-focused, there is a strong showing from companies like Lykos Therapeutics, Gilgamesh Pharmaceuticals, Freedom Biosciences, and Compass Pathways; as well as pharma heavy-hitters like Otsuka Pharmaceutical Companies (U.S.), AbbVie, and Biogen. In that sense, the fact that this isn't solely a psychedelics conference is a feature, not a bug, in that it offers an opportunity for psychedelic drug development to be situated within the broader drug development and pharmaceutical fields. You can access the agenda here: https://ter.li/uuhfnu

📢 We are excited to announce the release of the official program for the highly-anticipated 𝟮𝗻𝗱 𝗙𝗹𝘂𝗶𝗱 & 𝗜𝗺𝗮𝗴𝗶𝗻𝗴 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 & 𝗘𝗻𝗱𝗽𝗼𝗶𝗻𝘁𝘀 𝗶𝗻 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗦𝘂𝗺𝗺𝗶𝘁! Explore the 3-day program here: https://ter.li/us2y7d With the Donanemab ADCOM hailing fluid biomarkers as a deciding factor in the unanimous decision, improved plasma ptau 217 markers and PET tracers, α-syn self-seeding assay sensitivity, and enhanced NFL utility beyond SOD-1 ALS, 2024 has opened the floodgates for biomarker innovation. This year's summit returns with forward-thinking discussions to meaningfully advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics Join 90+ biomarker discovery scientists, imaging experts, neuroscience clinical program leaders, and regulatory leaders from renowned organizations like AbbVie, Alector, Biogen, Bristol Myers Squibb, Eli Lilly and Company, Eisai US, Pfizer, Takeda, Regeneron, The Michael J. Fox Foundation for Parkinson's Research, and many more at this unique industry-focused networking opportunity to advance precision medicine in Alzheimer's, Parkinson's, ALS & MS. 🧠 Learn more: https://ter.li/us2y7d 🎫 Register here: https://ter.li/gjvwyo Expert Speakers include: Jamie Eberling Katia Catherine Karalis, MD PhD ML (Maria-Laura) Blefari, Ph.D. Omar S. Mabrouk Pallavi Sachdev Rouba Kozak, Aarti Narang,PhD, Bradford Navia, MD, PhD, Bruno A. Benitez, M.D., Carol Singh, Chahin PACHAI, Cristian Salinas, Elpida Tsika, Enchi Liu, Erin Rosenbaugh, PhD, PMP, Jonathan D., Marla Weetall, Rema Raman PhD, Ruchi Gupta, Wesley Horton, Ying Wu #CNS #Neuroscience #ALS #Alzheimers #Parkinsons #Biomarkers #Neurodegenerative #Neuroinflammatory